Orthopedics This Week10d
When Surgery Isn’t an Option, This Knee Tumor May Still Be Treated
Overview: Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant ...
Le Lézard11d
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly ...
Le Lézard11d
GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children
Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children in Uganda, in an implementation science setting. This new pediatric treatment ...
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
Medical News Today16d
Betaseron interactions: Alcohol, medications, and other factors
pexidartinib (Turalio) — may increase the risk of liver damage pretomanid — may increase the risk of liver damage riluzole (Tiglutik) — may increase the risk of liver damage In some cases ...
WFMZ-TV19d
Night shift workers can reduce cancer risk by taking melatonin
Night shift workers can reduce their cancer risk by taking the sleep hormone melatonin, suggests a new study. Melatonin supplements may help offset cancer-causing DNA damage linked to shift work ...
MedCity News21d
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
BridgeBio Pharma has received European approval for a drug that treats cardiomyopathy stemming from a rare metabolic condition, strengthening the biotech’s position to take market share from the ...
Pharmabiz22d
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval
It becomes the second US Food and Drug Administration-approved drug for the disease after Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared by the US Food and ...
FiercePharma22d
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout Ono Pharmaceutical’s Deciphera Pharmaceuticals has won FDA approval for Romvimza as a competitor to Daiichi Sankyo’s Turalio in ...
mskcc.org25d
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT)
Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
MedCity News26d
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
Inhibiting CSF-1 to treat TGCT was validated by Turalio, a twice-daily Daiichi Sankyo drug that won its FDA approval in this indication in 2019. But Turalio’s label carries a black box warning ...
BioWorld26d
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
A phase III trial showed a higher objective response rate with Romvimza than a separate phase III trial showed with Daiichi Sankyo Co. Ltd.’s Turalio (pexidartinib), and the latter’s label contains a ...